Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition
Status:
Not yet recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
This is Phase 2, open label, non randomized single arm study to determine whether the
administration of vactosertib with durvalumab will provide meaningful increases in the
Overall Response Rate (ORR) in patients with urothelial cancers that fail to achieve a
response with anti-PD-1/PD-L1 based regimens